Federal Register of Legislation - Australian Government

Primary content

PB 1 of 2012 Lists as made
This instrument amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (No. PB 108 of 2010) to provide for additions, deletions and changes to drugs, forms, brands, responsible person codes, and the circumstances for prescribing various pharmaceutical benefits (including authority requirements).
Administered by: Health
Registered 14 Feb 2012
Tabling HistoryDate
Tabled HR15-Feb-2012
Tabled Senate27-Feb-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 1 of 2012

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012
(No.1)1

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 7 February 2012

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 1).

            (2)        This Instrument may also be cited as PB 1 of 2012.

2          Commencement

            This Instrument commences on 1 March 2012.

3          Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)

            Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).



Schedule 1     Amendments

 

[1]           Schedule 1, entry for Abacavir with Lamivudine and Zidovudine

omit from the column headed “Circumstances”:

C3590

C3591

C3592

C3593

substitute:

C3979

C3980

C3981

C3982

[2]           Schedule 1, entry for Adefovir

omit from the column headed “Circumstances”:

C3863

C3864

substitute:

C3971

C3972

C3973

C3974

[3]           Schedule 1, entry for Amlodipine in the form Tablet 5 mg (as besylate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Amlodipine 5

DO

MP NP

 

 

30

5

 

[4]           Schedule 1, entry for Amlodipine in the form Tablet 10 mg (as besylate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Amlodipine 10

DO

MP NP

 

 

30

5

 

[5]           Schedule 1, entry for Amlodipine with valsartan and hydrochlorothiazide

omit from the column headed “Authorised Prescriber” (all instances): MP         substitute:             MP NP

[6]           Schedule 1, entry for Atenolol in the form Tablet 50 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Atenolol-PS

FZ

MP NP

 

 

30

5

 

[7]           Schedule 1, entry for Bisoprolol in each of the forms: Tablet containing bisoprolol fumarate 2.5 mg; Tablet containing bisoprolol fumarate 5 mg; and Tablet containing bisoprolol fumarate 10 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Bisoprolol Pfizer

FZ

MP NP

C3234

 

28

5

 

[8]           Schedule 1, entry for Calcitriol in the form Capsule 0.25 microgram

(a)           omit from the column headed “Brand”:         Calcitriol-DP                     substitute:             Calciprox

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Calcitriol-PS

FZ

MP NP

C1165 C1166 C1167 C1467 C2636

 

100

3

 

[9]           Schedule 1, entry for Cefaclor in the form Tablet (sustained release) 375 mg (as monohydrate)

(a)           omit:

 

 

 

Douglas Cefaclor-CD

GM

PDP

 

 

10

0

 

(b)           omit:

 

 

 

Douglas Cefaclor-CD

GM

MP

 

 

10

1

 

[10]         Schedule 1, entry for Cephalexin in the form Capsule 250 mg (anhydrous) [Max Quantity 20; Number of Repeats 0]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Cephalexin-PS

FZ

PDP

 

 

20

0

 

[11]         Schedule 1, entry for Cephalexin in the form Capsule 250 mg (anhydrous) [Max Quantity 20; Number of Repeats 1]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Cephalexin-PS

FZ

MP NP MW

 

 

20

1

 

[12]         Schedule 1, entry for Cephalexin in the form Capsule 500 mg (anhydrous) [Max Quantity 20; Number of Repeats 0]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Cephalexin-PS

FZ

PDP

 

 

20

0

 

[13]         Schedule 1, entry for Cephalexin in the form Capsule 500 mg (anhydrous) [Max Quantity 20; Number of Repeats 1]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Cephalexin-PS

FZ

MP NP MW

 

 

20

1

 

[14]         Schedule 1, after entry for Choriogonadotropin alfa in the form Solution for injection 250 micrograms in 0.5 mL pre-filled syringe

insert in the columns in the order indicated:

 

Solution for injection 250 micrograms in 0.5 mL pre-filled pen

Injection

Ovidrel

SG

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

[15]         Schedule 1, entry for Ciprofloxacin in each of the forms: Tablet 500 mg (as hydrochloride); and Tablet 750 mg (as hydrochloride)

(a)        omit:

 

 

 

Ascent Pharmaceuticals Limited

GN

MP NP

C1431 C1432 C1572 C1573

 

14

0

 

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Ciprofloxacin-PS

FZ

MP NP

C1431 C1432 C1572 C1573

 

14

0

 

[16]         Schedule 1, entry for Citalopram in the form Tablet 20 mg (as hydrobromide)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Citalopram 20

DO

MP NP

C1211

 

28

5

 

[17]         Schedule 1, entry for Citalopram in the form Tablet 40 mg (as hydrobromide)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Citalopram 40

DO

MP NP

C1211

 

28

5

 


[18]         Schedule 1, after entry for Darunavir in the form Tablet 400 mg (as ethanolate)

insert in the columns in the order indicated:

 

Tablet 600 mg (as ethanolate)

Oral

Prezista

JC

MP
See Note 1

C3594 C3595

 

120

5

D

[19]         Schedule 1, entry for Denosumab in the form Injection 60 mg in 1 mL in pre-filled syringe

(a)           omit from the column headed “Authorised Prescriber”:            MP                       substitute:             MP NP

(b)        omit from the column headed “Circumstances”:

 

C3579

C3580

substitute:

C2758

C3987

[20]         Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 5 mg

omit:

 

 

 

Enalapril-DP 5mg

GN

MP NP

 

 

30

5

 

[21]         Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 10 mg

omit:

 

 

 

Enalapril-DP 10mg

GN

MP NP

 

 

30

5

 

[22]         Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 20 mg

omit:

 

 

 

Enalapril-DP 20mg

GN

MP NP

 

 

30

5

 


[23]         Schedule 1, entry for Entecavir in the form Tablet containing entecavir monohydrate 0.5 mg

omit from the column headed “Circumstances”:

C3871

C3872

substitute:

C3959

C3960

C3961

C3962

[24]         Schedule 1, entry for Entecavir in the form Tablet containing entecavir monohydrate 1 mg

omit from the column headed “Circumstances”:

C3873

C3874

substitute:

C3963

C3964

C3965

C3966

[25]         Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Epirubicin Actavis 10

TA

MP
See Note 1

 

 

See Note 3

See Note 3

D

[26]         Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Epirubicin Actavis 20

TA

MP
See Note 1

 

 

See Note 3

See Note 3

D

[27]         Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Epirubicin Actavis 50

TA

MP
See Note 1

 

 

See Note 3

See Note 3

D


[28]         Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Epirubicin Actavis 100

TA

MP
See Note 1

 

 

See Note 3

See Note 3

D

[29]         Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Epirubicin Actavis 200

TA

MP
See Note 1

 

 

See Note 3

See Note 3

D

[30]         Schedule 1, entry for Escitalopram in each of the forms: Tablet 10 mg (as oxalate); and Tablet 20 mg (as oxalate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Escitalopram GA

GN

MP NP

C1211

 

28

5

 

[31]         Schedule 1, entry for Essential Amino Acids Formula

(a)        omit from the column headed “Form”:           Oral powder 200 g, 2                     substitute:             Oral powder 200 g

(b)        omit from the column headed “Max Quantity”:           3              substitute:             6

[32]         Schedule 1, entry for Exemestane in the form Tablet 25 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Exemestane Sandoz

SZ

MP NP

C1541 C2457

 

30

5

 

[33]         Schedule 1, entry for Exenatide in each of the forms: Injection solution 5 micrograms per dose in pre-filled pen, 60 doses; and Injection solution 10 micrograms per dose in pre-filled pen, 60 doses

omit from the column headed “Circumstances”:

C3536

C3538

C3676

C3677

substitute:

C3540

C3542


[34]         Schedule 1, entry for Famotidine in the form Tablet 20 mg

omit:

 

 

 

Pepcidine M

MK

MP NP

 

 

60

5

 

[35]         Schedule 1, after entry for Filgrastim in the form Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)

insert in the columns in the order indicated:

 

Injection 300 micrograms in 0.5 mL single use pre-filled syringe (TevaGrastim)

Injection

TevaGrastim

AS

MP
See Note 1

C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 C3833 C3834

 

20

11

D

[36]         Schedule 1, after entry for Filgrastim in the form Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)

insert in the columns in the order indicated:

 

Injection 480 micrograms in 0.8 mL single use pre-filled syringe (TevaGrastim)

Injection

TevaGrastim

AS

MP
See Note 1

C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 C3833 C3834

 

20

11

D

[37]         Schedule 1, entry for Fluoxetine in the form Capsule 20 mg (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Fluoxetine-PS

FZ

MP NP

C1211 C1241

 

28

5

 

[38]         Schedule 1, entry for Foscarnet in the form I.V. infusion containing foscarnet sodium 24 mg per mL, 250 mL

omit from the column headed “Responsible Person”:                 AP          substitute:             IX

[39]         Schedule 1, entry for Gemcitabine in all forms

omit from the column headed “Circumstances” (leave column blank in all instances):

C1193

C1194

C1740

C2069

C2141

C3889

C3890

C3906

C3913

C3914

[40]         Schedule 1, after entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride) [Gemcitabine Kabi]

insert in the columns in the order indicated:

 

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 5 mL

Injection

Gemcitabine Ebewe

SZ

MP
See Note 1

 

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 1 g (as hydrochloride) in 25 mL

Injection

Gemcitabine Ebewe

SZ

MP
See Note 1

 

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 2 g (as hydrochloride) in 50 mL

Injection

Gemcitabine Ebewe

SZ

MP
See Note 1

 

 

See Note 3

See Note 3

D

[41]         Schedule 1, entry for Interferon Alfa-2a in the form Injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe [Max Quantity 30; Number of Repeats 5]

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[42]         Schedule 1, entry for Interferon Alfa-2a in the form Injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe [Max Quantity 30; Number of Repeats 5]

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[43]         Schedule 1, entry for Interferon Alfa-2a in the form Injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe [Max Quantity 30; Number of Repeats 5]

omit from the column headed “Circumstances”:

C3869  C3870

substitute:

C3959

C3960

C3961

C3962

[44]         Schedule 1, entry for Interferon Alfa-2a in the form Injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe [Max Quantity 30; Number of Repeats 5]

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[45]         Schedule 1, entry for Interferon Alfa-2b in each of the forms: Solution for injection 10,000,000 I.U. in 1 mL single dose vial; and Solution for injection 18,000,000 I.U. in 3 mL single dose vial

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[46]         Schedule 1, entry for Interferon Alfa-2b in the form Solution for injection 18,000,000 I.U. in 1.2 mL multi-dose injection pen
[Max Quantity 2; Number of Repeats 5]

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[47]         Schedule 1, entry for Interferon Alfa-2b in the form Solution for injection 25,000,000 I.U. in 2.5 mL single dose vial

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[48]         Schedule 1, entry for Interferon Alfa-2b in the form Solution for injection 60,000,000 I.U. in 1.2 mL multi-dose injection pen

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[49]         Schedule 1, entry for Interferon Alfa-2b in the form Solution for injection 30,000,000 I.U. in 1.2 mL multi-dose injection pen [Max Quantity 2; Number of Repeats 5]

omit from the column headed “Circumstances”:

C3869

C3870

substitute:

C3959

C3960

C3961

C3962

[50]         Schedule 1, entry for Lamivudine in each of the forms: Tablet 100 mg; and Oral solution 5 mg per mL, 240 mL

omit from the column headed “Circumstances”:

C3871

C3872

substitute:

C3959

C3960

C3961

C3962

[51]         Schedule 1, entry for Lamotrigine in each of the forms: Tablet 25 mg; Tablet 50 mg; Tablet 100 mg; and Tablet 200 mg

(a)        omit:

 

 

 

Lamotrigine-DP

GM

MP NP

C1426

 

56

5

 

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Lamotrigine-PS

FZ

MP NP

C1426

 

56

5

 

[52]         Schedule 1, after entry for Lignocaine in the form Infusion containing lignocaine hydrochloride 500 mg in 5 mL

insert in the columns in the order indicated:

Linagliptin

Tablet 5 mg

Oral

Trajenta

BY

MP NP

C3540

 

30

5

 

[53]         Schedule 1, entry for Lisinopril in each of the forms: Tablet 5 mg; Tablet 10 mg; and Tablet 20 mg

(a)        omit:

 

 

 

Liprace

GM

MP NP

 

 

30

5

 

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Lisinopril-PS

FZ

MP NP

 

 

30

5

 

[54]         Schedule 1, entry for Medroxyprogesterone in the form Tablet containing medroxyprogesterone acetate 10 mg

omit:

 

 

 

Medroxyhexal

HX

MP NP

 

 

30

2

 

[55]         Schedule 1, entry for Metformin in the form Tablet containing metformin hydrochloride 500 mg

omit:

 

 

 

Ascent Pharmaceuticals Limited

GN

MP NP

 

 

100

5

 


[56]         Schedule 1, entry for Metformin in the form Tablet containing metformin hydrochloride 850 mg

omit:

 

 

 

Ascent Pharmaceuticals Limited

GN

MP NP

 

 

60

5

 

[57]         Schedule 1, entry for Milk powder — lactose free formula

omit:

 

Oral powder 900 g (Karicare De-Lact)

Oral

Karicare De-Lact

SB

MP NP

C2760 C2762

P2762

5

0

 

 

 

 

 

 

MP NP

C2760 C2762

P2760

5

5

 

[58]         Schedule 1, entry for Oestradiol in the form Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28

omit from the column headed “Responsible Person”:                 MK         substitute:             AS

[59]         Schedule 1, entry for Omeprazole in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 1]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Omeprazole-PS

FZ

MP NP

C1177 C1337 C1476 C1533

P1177

30

1

 

[60]         Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30; Number of Repeats 2]

(a)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Panthron

GN

MP NP

C1177 C1337 C1476 C1533

P1177

30

2

 

(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Pantoprazole-PS

FZ

MP NP

C1177 C1337 C1476 C1533

P1177

30

2

 


[61]         Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30; Number of Repeats 5]

(a)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Panthron

GN

MP NP

C1177 C1337 C1476 C1533

P1337 P1476 P1533

30

5

 

(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Pantoprazole-PS

FZ

MP NP

C1177 C1337 C1476 C1533

P1337 P1476 P1533

30

5

 

[62]         Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 20 mg (as sodium sesquihydrate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Pantoprazole-PS

FZ

MP NP

C1533

 

30

5

 

[63]         Schedule 1, entry for Paroxetine in the form Tablet 20 mg (as hydrochloride)

omit:

 

 

 

Paroxetine-DP

GM

MP NP

C1211 C1241 C1862

 

30

5

 

[64]         Schedule 1, entry for Peginterferon Alfa-2a in each of the forms: Injection 135 micrograms in 0.5 mL single use pre-filled syringe; and Injection 180 micrograms in 0.5 mL single use pre-filled syringe

omit from the column headed “Circumstances”:

C3867

C3868

substitute:

C3975

C3976

C3977

C3978


[65]         Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg

(a)           omit:

 

 

 

Pravastatin 10

MI

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

(b)           omit:

 

 

 

Pravastatin 10

MI

MP

C1540 C3047

P3047

30

11

 

[66]         Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg

(a)           omit:

 

 

 

Pravastatin 20

MI

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

(b)           omit:

 

 

 

Pravastatin 20

MI

MP

C1540 C3047

P3047

30

11

 

[67]         Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg

(a)           omit:

 

 

 

Pravastatin 40

MI

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

(b)           omit:

 

 

 

Pravastatin 40

MI

MP

C1540 C3047

P3047

30

11

 

[68]         Schedule 1, entry for Prochlorperazine in the form Tablet containing prochlorperazine maleate 5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Prochlorperazine-PS

FZ

PDP MP NP

 

 

25

0

 


[69]         Schedule 1, entry for Protein hydrolysate formula with medium chain triglycerides

omit:

 

Oral powder 450 g (Pepti-Junior Gold)

Oral

Pepti-Junior Gold

SB

MP NP

C1034 C1059 C1080 C1092 C1310 C1364 C1670 C2567 C2806 C2811 C2812 C2813 C2814 C2815

 

8

5

 

[70]         Schedule 1, entry for Ramipril in each of the forms: Capsule 1.25 mg; Capsule 2.5 mg; and Capsule 5 mg

omit:

 

 

 

Ramipril-DP

GN

MP NP

 

 

30

5

 

[71]         Schedule 1, entry for Ramipril in the form Capsule 10 mg

(a)           omit:

 

 

 

Ramipril-DP

GN

MP NP

 

 

30

5

 

(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Ramipril-PS

FZ

MP NP

 

 

30

5

 

[72]         Schedule 1, entry for Ranitidine in the form Tablet 150 mg (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Ranitidine-PS

FZ

MP NP MW

 

 

60

5

 

[73]         Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2061 C3083

P2061 P3083

60

2

 


[74]         Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2061 C3083

P1589

60

5

 

[75]         Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2061 C2272 C3083

P2061 P3083

60

2

 

[76]         Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2061 C2272 C3083

P1589 P2272

60

5

 

[77]         Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2272 C3083

P3083

60

2

 

[78]         Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2272 C3083

P1589 P2272

60

5

 

[79]         Schedule 1, entry for Risperidone in each of the forms: Tablet 3 mg; and Tablet 4 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Risperidone Pfizer

FZ

MP NP

C1589 C2272

 

60

5

 


[80]         Schedule 1, entry for Roxithromycin in the form Tablet 150 mg

(a)        omit:

 

 

 

Roxide

HX

PDP

 

 

10

0

 

(b)        omit:

 

 

 

Roxide

HX

MP NP

 

 

10

1

 

[81]         Schedule 1, entry for Roxithromycin in the form Tablet 300 mg

(a)        omit:

 

 

 

Roxide

HX

PDP

 

 

5

0

 

(b)        omit:

 

 

 

Roxide

HX

MP NP

 

 

5

1

 

[82]         Schedule 1, entry for Sertraline in the form Tablet 50 mg (as hydrochloride)

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Sertraline 50

DO

MP NP

C1211 C1241 C1975

 

30

5

 

(b)           omit:

 

 

 

Concorz

HX

MP NP

C1211

 

30

5

 

[83]         Schedule 1, entry for Sertraline in the form Tablet 100 mg (as hydrochloride)

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Sertraline 100

DO

MP NP

C1211 C1241 C1975

 

30

5

 

(b)           omit:

 

 

 

Concorz

HX

MP NP

C1211

 

30

5

 


[84]         Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 10

DO

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

[85]         Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 11]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 10

DO

MP

C1540 C3047

P3047

30

11

 

[86]         Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 20

DO

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

[87]         Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 11]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 20

DO

MP

C1540 C3047

P3047

30

11

 

[88]         Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Max Quantity 30; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 40

DO

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

[89]         Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Max Quantity 30; Number of Repeats 11]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 40

DO

MP

C1540 C3047

P3047

30

11

 


[90]         Schedule 1, entry for Simvastatin in the form Tablet 80 mg [Max Quantity 30; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 80

DO

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

[91]         Schedule 1, entry for Simvastatin in the form Tablet 80 mg [Max Quantity 30; Number of Repeats 11]

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Auro-Simvastatin 80

DO

MP

C1540 C3047

P3047

30

11

 

(b)        omit from the column headed “Responsible Person” for the brand “Simvastatin Sandoz”:                              CR                substitute:             SZ

[92]         Schedule 1, after entry for Somatropin in the form Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative) [Norditropin SimpleXx]

insert in the columns in the order indicated:

 

Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative)

Injection

Saizen

SG

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Saizen

SG

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative)

Injection

Saizen

SG

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

[93]         Schedule 1, entry for Telbivudine

omit from the column headed “Circumstances”:

C3865

C3866

substitute:

C3967

C3968

C3969

C3970


[94]         Schedule 1, entry for Tenofovir

omit from the column headed “Circumstances”:

C3863

C3864

C3865

C3866

substitute:

C3967

C3968

C3969

C3970

C3971

C3972

C3973

C3974

[95]         Schedule 1, entry for Tenofovir with emtricitabine and efavirenz

omit from the column headed “Circumstances”:

C3586

C3587

C3588

C3589

substitute:

C3983

C3984

C3985

C3986

[96]         Schedule 3, after details relevant to Responsible person code CX

insert:

DO

Aurobindo Pharma (Australia) Pty Limited

 45 118 452 369

[97]         Schedule 3, after details relevant to Responsible person code IS

insert:

IX

Clinect Pty Ltd

 76 150 558 473


[98]         Schedule 3, details relevant to Responsible person code VP

insert in the column headed “ABN”:              61 140 839 658

[99]         Schedule 4, Part 1, entry for Abacavir with Lamivudine and Zidovudine

substitute:

Abacavir with Lamivudine and Zidovudine

C3979

 

Where the patient is receiving treatment at/from a private hospital

Initial treatment of human immunodeficiency virus (HIV) infection in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

Compliance with Written or Telephone Authority Required procedures

 

C3980

 

Where the patient is receiving treatment at/from a private hospital

Continuing treatment of human immunodeficiency virus (HIV) infection where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection

Compliance with Written or Telephone Authority Required procedures

 

C3981

 

Where the patient is receiving treatment at/from a public hospital

Initial treatment of human immunodeficiency virus (HIV) infection in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3981

 

C3982

 

Where the patient is receiving treatment at/from a public hospital

Continuing treatment of human immunodeficiency virus (HIV) infection where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3982


[100]       Schedule 4, Part 1, entry for Adalimumab [Circumstances Code 3743]

omit all text from the column headed “Authority Requirements – Part of Circumstances” and substitute:

Compliance with
Written Authority
Required procedures

[101]       Schedule 4, Part 1, entry for Adalimumab [part of Circumstances Code 3743—line commencing “Continuation of a course of
initial treatment, …….”]

insert in the column headed “Authority Requirements – Part of Circumstances” (currently having no corresponding text):

Compliance with
Written or Telephone Authority Required procedures

[102]       Schedule 4, Part 1, entry for Adefovir

substitute:

Adefovir

C3971

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance

Compliance with Written or Telephone Authority Required procedures

 

C3972

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures


 

 

C3973

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3973

 

C3974

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3974

[103]       Schedule 4, Part 1, entry for Denosumab

substitute:

Denosumab

C1035

 

Bone metastases from breast cancer

Compliance with Authority Required procedures

 

C2758

 

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years or older with a bone mineral density T-score of -3.0 or less, and where the date, site (femoral neck or lumbar spine) and score of the qualifying bone mineral density measurement are documented in the patient's medical records when treatment is initiated

Compliance with Authority Required procedures - Streamlined Authority Code 2758



 

 

C3881

 

Bone metastases from hormone-resistant prostate cancer

Compliance with Authority Required procedures

 

C3987

 

Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in a woman with fracture due to minimal trauma, where the fracture has been demonstrated radiologically and the year of plain x-ray or computed tomography scan or magnetic resonance imaging scan is documented in the patient's medical records when treatment is initiated, provided that if the fracture is a vertebral fracture, there is a 20% or greater reduction in height of the anterior or mid portion of the affected vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body

Compliance with Authority Required procedures - Streamlined Authority Code 3987


[104]       Schedule 4, Part 1, entry for Entecavir

substitute:

Entecavir

C3959

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3960

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures

 

C3961

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3961



 

 

C3962

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3962


 

C3963

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who has failed lamivudine and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance

Compliance with Written or Telephone Authority Required procedures

 

C3964

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B
Chronic hepatitis B in a patient without cirrhosis who has failed lamivudine and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3964


 

C3965

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has failed lamivudine and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures


 

 

C3966

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has failed lamivudine and who has detectable HBV DNA
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3966

[105]       Schedule 4, Part 1, entry for Exenatide

substitute:

Exenatide

C3540

 

Treatment of type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient in whom a combination of metformin and a sulfonylurea is contraindicated or not tolerated, and:
(a) whose glycosylated haemoglobin (HbA1c) prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 is greater than 7%, despite treatment with either metformin or a sulfonylurea; or
(b) as an alternative to HbA1c level measurement in the case of patients who have clinical conditions with reduced red blood cell survival (including haemolytic anaemias and haemoglobinopathies) and/or who have had red cell transfusion within the previous 3 months — where blood glucose monitoring over a 2 week period prior to initiation of a gliptin, a glitazone or a glucagon-like peptide-1 shows blood glucose levels greater than 10 mmol per L in more than 20% of tests, despite treatment with either metformin or a sulfonylurea; and
where the qualifying HbA1c level and date of measurement, or the results of the blood glucose monitoring, whichever are applicable in the circumstances, are documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated; and
where the qualifying HbA1c level and the results of the blood glucose monitoring are no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated

Compliance with Authority Required procedures - Streamlined Authority Code 3540


 

 

C3542

 

Treatment of type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient:
(a) whose glycosylated haemoglobin (HbA1c) prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 is greater than 7%, despite treatment with maximally tolerated doses of metformin and a sulfonylurea; or
(b) as an alternative to HbA1c level measurement in the case of patients who have clinical conditions with reduced red blood cell survival (including haemolytic anaemias and haemoglobinopathies) and/or who have had red cell transfusion within the previous 3 months — where blood glucose monitoring over a 2 week period prior to initiation of a gliptin, a glitazone or a glucagon-like peptide-1 shows blood glucose levels greater than 10 mmol per L in more than 20% of tests, despite treatment with maximally tolerated doses of metformin and a sulfonylurea; and

where the qualifying HbA1c level and date of measurement, or the results of the blood glucose monitoring, whichever are applicable in the circumstances, are documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated; and
where the qualifying HbA1c level and the results of the blood glucose monitoring are no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated

Compliance with Authority Required procedures - Streamlined Authority Code 3542

[106]       Schedule 4, Part 1, omit entry for Gemcitabine

[107]       Schedule 4, Part 1, entry for Interferon Alfa-2a

(a)           omit:

 

C3869

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Is not a person with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L)

Compliance with Written or Telephone Authority Required procedures


 

 

C3870

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAG positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAG negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Is not a person with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L)

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3870

(b)           insert after existing text in the columns in the order indicated:

 

C3959

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3960

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures

 

C3961

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3961


 

 

C3962

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3962

[108]       Schedule 4, Part 1, entry for Interferon Alfa-2b

(a)           omit:

 

C3869

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Is not a person with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L)

Compliance with Written or Telephone Authority Required procedures

 

C3870

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAG positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAG negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Is not a person with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L)

Compliance with  Written or Telephone Authority Required procedures - Streamlined Authority Code 3870

(b)           insert after existing text in the columns in the order indicated:

 

C3959

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3960

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures

 

C3961

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3961

 

C3962

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3962

[109]       Schedule 4, Part 1, entry for Lamivudine

omit:

 

C3871

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3872

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAG positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAG negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3872


substitute:

 

C3959

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3960

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with  Written or Telephone Authority Required procedures

 

C3961

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3961


 

 

C3962

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3962

[110]       Schedule 4, Part 1, after entry for Levonorgestrel

insert:

Linagliptin

C3540

 

Treatment of type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient in whom a combination of metformin and a sulfonylurea is contraindicated or not tolerated, and:
(a) whose glycosylated haemoglobin (HbA1c) prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 is greater than 7%, despite treatment with either metformin or a sulfonylurea; or
(b) as an alternative to HbA1c level measurement in the case of patients who have clinical conditions with reduced red blood cell survival (including haemolytic anaemias and haemoglobinopathies) and/or who have had red cell transfusion within the previous 3 months — where blood glucose monitoring over a 2 week period prior to initiation of a gliptin, a glitazone or a glucagon-like peptide-1 shows blood glucose levels greater than 10 mmol per L in more than 20% of tests, despite treatment with either metformin or a sulfonylurea; and
where the qualifying HbA1c level and date of measurement, or the results of the blood glucose monitoring, whichever are applicable in the circumstances, are documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated; and
where the qualifying HbA1c level and the results of the blood glucose monitoring are no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated

Compliance with Authority Required procedures - Streamlined Authority Code 3540


[111]       Schedule 4, Part 1, entry for Peginterferon Alfa-2a

omit:

 

C3867

 

Where the patient is receiving treatment at/from a private hospital

Monotherapy in a patient with chronic hepatitis B and compensated liver disease who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Have received no prior peginterferon alfa therapy for the treatment of hepatitis B;
(4) Is not a person with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L).
Treatment is limited to 1 course of treatment for a duration of up to 48 weeks

Compliance with Written or Telephone Authority Required procedures

 

C3868

 

Where the patient is receiving treatment at/from a public hospital

Monotherapy in a patient with chronic hepatitis B who and compensated liver disease who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAG positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAG negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Have received no prior peginterferon alfa therapy for the treatment of hepatitis B;
(4) Is not a person with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L.
Treatment is limited to 1 course of treatment for a duration of up to 48 weeks

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3868

substitute:

 

C3975

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B

Compliance with Written or Telephone Authority Required procedures

 

C3976

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Treatment is limited to 1 course of treatment for a duration of up to 48 weeks

Compliance with Written or Telephone Authority Required procedures

 

C3977

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy;
(3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3977


 

C3978

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.
Treatment is limited to 1 course of treatment for a duration of up to 48 weeks

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3978


[112]       Schedule 4, Part 1, entry for Telbivudine

substitute:

Telbivudine

C3967

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures

 

C3968

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3969

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3969


 

C3970

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3970



[113]       Schedule 4, Part 1, entry for Tenofovir

omit:

 

C3863

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance.
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3864

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B
Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance.
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3864

 

C3865

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy.
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3866

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAG positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAG negative - in conjunction with documented hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy.
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3866

substitute:

 

C3967

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures

 

C3968

 

Where the patient is receiving treatment at/from a private hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3969

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
(2) Evidence of chronic liver injury as determined by:
(a) Confirmed elevated serum ALT; or
(b) Liver biopsy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3969



 

 

C3970

 

Where the patient is receiving treatment at/from a public hospital

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3970


 

C3971

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance

Compliance with Written or Telephone Authority Required procedures

 

C3972

 

Where the patient is receiving treatment at/from a private hospital

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures

 

C3973

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3973



 

 

C3974

 

Where the patient is receiving treatment at/from a public hospital

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3974

[114]       Schedule 4, Part 1, entry for Tenofovir with emtricitabine and efavirenz

substitute:

Tenofovir with emtricitabine and efavirenz

C3983

 

Where the patient is receiving treatment at/from a private hospital

Initial treatment of human immunodeficiency virus (HIV) infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

Compliance with Written or Telephone Authority Required procedures

 

C3984

 

Where the patient is receiving treatment at/from a private hospital

Continuing treatment of human immunodeficiency virus (HIV) infection where the patient has previously received PBS-subsidised therapy for HIV infection

Compliance with Written or Telephone Authority Required procedures

 

C3985

 

Where the patient is receiving treatment at/from a public hospital

Initial treatment of human immunodeficiency virus (HIV) infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3985

 

C3986

 

Where the patient is receiving treatment at/from a public hospital

Continuing treatment of human immunodeficiency virus (HIV) infection where the patient has previously received PBS-subsidised therapy for HIV infection

Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3986

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.